Investing.com - Neximmune reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Neximmune announced earnings per share of $-0.60 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.70 on revenue of $0.00.
Neximmune shares are down 30% from the beginning of the year , still down 95.88% from its 52 week high of $11.41 set on Thursday, November 18, 2021.
Neximmune follows other major Healthcare sector earnings this month
Neximmune's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar